---
title: "FDA Approves Expanded Use of GE HealthCare's Vizamyl for Enhanced Alzheimer's Diagnosis and Monitoring"
description: "GE HealthCare Technologies Inc. announced that the FDA has approved an updated label for its PET imaging agent VizamylTM, enhancing its use for beta-amyloid detection in Alzheimer's diagnosis and moni"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/245959773.md"
published_at: "2025-06-24T18:16:18.000Z"
---

# FDA Approves Expanded Use of GE HealthCare's Vizamyl for Enhanced Alzheimer's Diagnosis and Monitoring

> GE HealthCare Technologies Inc. announced that the FDA has approved an updated label for its PET imaging agent VizamylTM, enhancing its use for beta-amyloid detection in Alzheimer's diagnosis and monitoring. The approval allows for quantitative analysis and removes previous limitations on monitoring patient response to anti-amyloid therapy, improving personalized care for patients. This marks a significant milestone for GE HealthCare’s Pharmaceutical Diagnostics division, supporting better healthcare outcomes.

GE HealthCare Technologies Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved an updated label for its PET imaging agent VizamylTM (flutemetamol F 18 injection) for beta-amyloid detection. The approval expands the indications for Vizamyl’s use, incorporating quantitative analysis capabilities and eliminating previous limitations on monitoring patient response to anti-amyloid therapy. These changes enhance clinicians’ ability to diagnose and monitor Alzheimer’s disease, enabling more precise and personalized care for patients and their families. This regulatory approval marks a significant milestone for GE HealthCare’s Pharmaceutical Diagnostics division, further supporting improved healthcare outcomes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GE HealthCare Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250624101667) on June 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [GEHC.US - GE HealthCare Tech](https://longbridge.com/en/quote/GEHC.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sivik Global Healthcare LLC Invests $1.88 Million in GE HealthCare Technologies Inc. $GEHC | Sivik Global Healthcare LLC has invested $1.88 million in GE HealthCare Technologies Inc., acquiring 25,000 shares in th | [Link](https://longbridge.com/en/news/271790235.md) |
| GE HealthCare Technologies (NASDAQ:GEHC) Posts Earnings Results, Beats Estimates By $0.01 EPS | GE HealthCare Technologies (NASDAQ:GEHC) reported earnings of $1.44 per share, exceeding estimates by $0.01. The company | [Link](https://longbridge.com/en/news/274836479.md) |
| A Glimpse Into The Expert Outlook On GE HealthCare Techs Through 10 Analysts | Analysts have provided mixed ratings for GE HealthCare Techs (NASDAQ:GEHC) over the past three months, with a total of 4 | [Link](https://longbridge.com/en/news/271825371.md) |
| (GEHC) GE Healthcare Technologies Expects Full Year 2026 Adjusted EPS Range $4.95 - $5.15, vs. FactSet Est of $4.94 | (GEHC) GE Healthcare Technologies Expects Full Year 2026 Adjusted EPS Range $4.95 - $5.15, vs. FactSet Est of $4.94 | [Link](https://longbridge.com/en/news/274803030.md) |
| GE HealthCare Receives FDA 510(k) Clearance and CE Mark for Allia Moveo | GE HealthCare Technologies Inc. has received FDA 510(k) clearance and CE Mark for its Allia Moveo platform, designed to  | [Link](https://longbridge.com/en/news/274517393.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.